Specifying a GLP Six-Month Tg.rasH2 Mouse Carcinogenicity Study for a CNS-Directed Antisense Oligonucleotide: A Request-for-Proposal Framework Supporting a Postmarketing Nonclinical Commitment

A therapy that works by lowering expression of a disease-driving protein may be givenrepeatedly for years, so the absence of a tumour signal in a small pre-approval population is notevidence that none exists. This article builds a request for proposal (RFP) for a contract researchorganization (CRO) to conduct a GLP six-month Tg.rasH2 mouse carcinogenicity study of ahypothetical intrathecally administered antisense oligonucleotide authorized for an ultra-rareprogressive neurological disease, as one element of a postmarketing nonclinical commitment thatalso includes a separate two-year rat bioassay. It sets out the weight-of-evidence rationale underICH S1A, S1B(R1), and S1C(R2), the design questions that only the vendor can answer with thesponsor's complete data package (dose, route, frequency, exposure confirmation), pathology andstatistical requirements, a 21-month schedule measured from award, a planning budget of USD900,000 to 1,400,000, and weighted selection criteria. Recommendations address data handling,confidentiality, and intellectual property.Keywords: request for proposal; carcinogenicity; Tg.rasH2; antisense oligonucleotide; ICHS1B(R1); weight of evidence; GLP; postmarketing commitment

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425532
Primary Topic
Carcinogens and Genotoxicity Assessment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specifying a GLP Six-Month Tg.rasH2 Mouse Carcinogenicity Study for a CNS-Directed Antisense Oligonucleotide: A Request-for-Proposal Framework Supporting a Postmarketing Nonclinical Commitment

Peivand Pirouzi, Junyi Wu, Atchaya Ravichandran
Zenodo (CERN European Organization for Nuclear Research)
Carcinogens and Genotoxicity Assessment
article

Specifying a GLP Six-Month Tg.rasH2 Mouse Carcinogenicity Study for a CNS-Directed Antisense Oligonucleotide: A Request-for-Proposal Framework Supporting a Postmarketing Nonclinical Commitment

Peivand Pirouzi, Junyi Wu, Atchaya Ravichandran
article en

Abstract

A therapy that works by lowering expression of a disease-driving protein may be givenrepeatedly for years, so the absence of a tumour signal in a small pre-approval population is notevidence that none exists. This article builds a request for proposal (RFP) for a contract researchorganization (CRO) to conduct a GLP six-month Tg.rasH2 mouse carcinogenicity study of ahypothetical intrathecally administered antisense oligonucleotide authorized for an ultra-rareprogressive neurological disease, as one element of a postmarketing nonclinical commitment thatalso includes a separate two-year rat bioassay. It sets out the weight-of-evidence rationale underICH S1A, S1B(R1), and S1C(R2), the design questions that only the vendor can answer with thesponsor's complete data package (dose, route, frequency, exposure confirmation), pathology andstatistical requirements, a 21-month schedule measured from award, a planning budget of USD900,000 to 1,400,000, and weighted selection criteria. Recommendations address data handling,confidentiality, and intellectual property.Keywords: request for proposal; carcinogenicity; Tg.rasH2; antisense oligonucleotide; ICHS1B(R1); weight of evidence; GLP; postmarketing commitment

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Carcinogens and Genotoxicity Assessment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Specifying a GLP Six-Month Tg.rasH2 Mouse Carcinogenicity Study for a CNS-Directed Antisense Oligonucleotide: A Request-for-Proposal Framework Supporting a Postmarketing Nonclinical Commitment — Peivand Pirouzi, Junyi Wu, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS